Byung-Gyu Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Byung-Gyu Kim has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Ehsan Malek
Roswell Park Comprehensive Cancer Center 2 Department of Medicine Buffalo, New York
73 shared publications - James Joseph Driscoll
Division of Hematology & Oncology, Case Western Reserve University, Cleveland, OH USA
72 shared publications - Drew Adams
Case Western Reserve University School of Medicine
69 shared publications - James J. Ignatz-Hoover
Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio
69 shared publications - Priyanka Shailendra Rana
Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio
69 shared publications - Timothy A. Chan
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA
69 shared publications
Latest Publications
- Open Access
- 4 November 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (3)
Piezo1 restrains proinflammatory response but is essential in T-cell–mediated immunopathology
Piezo1 is a mechanosensitive, nonselective Ca2+ channel which is broadly expressed in CD4+ T cells. Using lineage-specific Piezo1 knockout mice (Piezo1cKO), we show that loss of Piezo1 in CD4+ T cells significantly increased IFNγ and IL-17 production in vitro under TH1 and TH17 polarizing conditions, respectively. Despite their intrinsic proinflammatory phenotype, Piezo1cKO T cells are incapable of establishing disease in vivo in three separate adoptive transfer (AT) T cell-mediated inflammatory mouse models, including experimental autoimmune encephalomyelitis, inflammatory bowel disease (IBD), and graft versus-host disease. These phenomena coincided with a decreased effector memory (CD44hiCD62Llo) CD4+ T cell pool derived from donor Piezo1cKO T cells, an observation that is related to intrinsic T-cell fitness, as co-transfer IBD mouse model revealed a deficiency in the CD4+ effector memory population derived only from the naïve Piezo1cKO but not co-infused Piezo1WT CD4+ T cell source. Taken together, our results support Piezo1 as restraining proinflammatory T cell differentiation while contributing to the generation and persistence of the effector memory pool during CD4+ T cell-mediated immunopathology.
- 4 November 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (3)
Open AccessPiezo1 restrains proinflammatory response but is essential in T-cell–mediated immunopathology
Piezo1 is a mechanosensitive, nonselective Ca2+ channel which is broadly expressed in CD4+ T cells. Using lineage-specific Piezo1 knockout mice (Piezo1cKO), we show that loss of Piezo1 in CD4+ T cells significantly increased IFNγ and IL-17 production in vitro under TH1 and TH17 polarizing conditions, respectively. Despite their intrinsic proinflammatory phenotype, Piezo1cKO T cells are incapable of establishing disease in vivo in three separate adoptive transfer (AT) T cell-mediated inflammatory mouse models, including experimental autoimmune encephalomyelitis, inflammatory bowel disease (IBD), and graft versus-host disease. These phenomena coincided with a decreased effector memory (CD44hiCD62Llo) CD4+ T cell pool derived from donor Piezo1cKO T cells, an observation that is related to intrinsic T-cell fitness, as co-transfer IBD mouse model revealed a deficiency in the CD4+ effector memory population derived only from the naïve Piezo1cKO but not co-infused Piezo1WT CD4+ T cell source. Taken together, our results support Piezo1 as restraining proinflammatory T cell differentiation while contributing to the generation and persistence of the effector memory pool during CD4+ T cell-mediated immunopathology.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Figure S20 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S20. SDS-PAGE of HDAC6 KO cells. MM cells were either untreated or treated with sgRNA scrambled control or sgRNA specific to HDAC6. Following selection, cell lysates were prepared and electrophoresed on SDS gels, transferred to PVDF. Membranes were probed for HDAC6 using a knockout verified antibody (catalog number ab133493, Abcam, Waltham, MA) a dilution of 1:10,000.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S20 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S20. SDS-PAGE of HDAC6 KO cells. MM cells were either untreated or treated with sgRNA scrambled control or sgRNA specific to HDAC6. Following selection, cell lysates were prepared and electrophoresed on SDS gels, transferred to PVDF. Membranes were probed for HDAC6 using a knockout verified antibody (catalog number ab133493, Abcam, Waltham, MA) a dilution of 1:10,000.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Table S6 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Table S6. TAAgs regulated by proteasome activation or inhibition. Shown is the peptide sequence, gene accession number, mutation or PTM fold change in that peptide antigen following treatment with either tubastatin-A, ACY-738, or bortezomib. Green indicates upregulation and red indicates downregulation. Numbers indicate the fold-change relative to untreated RPMI-8226 cells. Arrows indicate direction of change for peptide sequences that were not detected in untreated cells. ND (blue) indicates that the peptide was not detected under the indicated condition. Blue asterisks indicate that the antigen was not detected in untreated cells and unmasked after treatment with the HDAC6 inhibitor.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Table S6. TAAgs regulated by proteasome activation or inhibition. Shown is the peptide sequence, gene accession number, mutation or PTM fold change in that peptide antigen following treatment with either tubastatin-A, ACY-738, or bortezomib. Green indicates upregulation and red indicates downregulation. Numbers indicate the fold-change relative to untreated RPMI-8226 cells. Arrows indicate direction of change for peptide sequences that were not detected in untreated cells. ND (blue) indicates that the peptide was not detected under the indicated condition. Blue asterisks indicate that the antigen was not detected in untreated cells and unmasked after treatment with the HDAC6 inhibitor.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S1. Conversion of the constitutive proteasome to immunoproteasome by IFN-γ-induced subunit substitution.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S1. Conversion of the constitutive proteasome to immunoproteasome by IFN-γ-induced subunit substitution.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Table S1. Top activators of proteasomal ChT-Like activity. Shown are the top pharmacologics that increased proteasome ChT-like in the HTS.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Table S1. Top activators of proteasomal ChT-Like activity. Shown are the top pharmacologics that increased proteasome ChT-like in the HTS.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S10. Effect of proteasome inhibitors on presentation of the SIINFEKL-MHC class I molecule complex. E.G7-Ova cells were treated with pharmacologics at the indicated concentration for 16 h. Cells were then stained with a monoclonal antibody to Ova 257-264 (SIINFEKL) peptide bound to H2Kb and quantitated using a BD-LSRII sorter interfaced with FlowJo software as above.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S10. Effect of proteasome inhibitors on presentation of the SIINFEKL-MHC class I molecule complex. E.G7-Ova cells were treated with pharmacologics at the indicated concentration for 16 h. Cells were then stained with a monoclonal antibody to Ova 257-264 (SIINFEKL) peptide bound to H2Kb and quantitated using a BD-LSRII sorter interfaced with FlowJo software as above.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Effect of HDAC6 inhibitors on the myeloma immunopeptidome. A, Number of peptides eluted from human MHC-I molecules at each indicated peptide lengths (range = 6 to 15 amino acids). RPMI-8226 cells were treated with tubastatin-A, ACY-738 or bortezomib. B, Number of peptides and their fold change after treatment of RPMI-8226 cells with tubastatin-A, ACY-738, or bortezomib. C, The terminal amino acids of the top 50 peptides upregulated by tubastatin-A or ACY-738 treatment were analyzed. Shown is the relative percent of each terminal amino acid for the top 50 peptides upregulated by HDAC6 inhibitor treatment. D, Shown is the number of peptides reduced by treatment of E.G7-Ova cells with bortezomib and the fold decrease relative to untreated cells. E, Shown is the peptide sequence, fold decrease, and gene accession for the 20 peptides most downregulated by bortezomib treatment. Red asterisks indicate peptides upregulated by treatment with both HDAC6 inhibitors. F, The terminal amino acids of the top 50 peptides upregulated by tubastatin-A or ACY-738 treatment were analyzed. Shown is the relative percent of each terminal amino acid for the top 50 peptides upregulated following treatment with each HDAC6 inhibitor. G, Shown are gene accession numbers for the top 20 peptides most downregulated by bortezomib treatment. H, Shown are gene accession numbers for the top 20 peptides most upregulated by either tubastatin-A or ACY-738. Red asterisks indicate genes and peptides that were upregulated following treatment with both of the HDAC6 inhibitors.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Effect of HDAC6 inhibitors on the myeloma immunopeptidome. A, Number of peptides eluted from human MHC-I molecules at each indicated peptide lengths (range = 6 to 15 amino acids). RPMI-8226 cells were treated with tubastatin-A, ACY-738 or bortezomib. B, Number of peptides and their fold change after treatment of RPMI-8226 cells with tubastatin-A, ACY-738, or bortezomib. C, The terminal amino acids of the top 50 peptides upregulated by tubastatin-A or ACY-738 treatment were analyzed. Shown is the relative percent of each terminal amino acid for the top 50 peptides upregulated by HDAC6 inhibitor treatment. D, Shown is the number of peptides reduced by treatment of E.G7-Ova cells with bortezomib and the fold decrease relative to untreated cells. E, Shown is the peptide sequence, fold decrease, and gene accession for the 20 peptides most downregulated by bortezomib treatment. Red asterisks indicate peptides upregulated by treatment with both HDAC6 inhibitors. F, The terminal amino acids of the top 50 peptides upregulated by tubastatin-A or ACY-738 treatment were analyzed. Shown is the relative percent of each terminal amino acid for the top 50 peptides upregulated following treatment with each HDAC6 inhibitor. G, Shown are gene accession numbers for the top 20 peptides most downregulated by bortezomib treatment. H, Shown are gene accession numbers for the top 20 peptides most upregulated by either tubastatin-A or ACY-738. Red asterisks indicate genes and peptides that were upregulated following treatment with both of the HDAC6 inhibitors.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S5. Effect of top pharmacologics on a. inhibition of proteasome ChT-like activity in MM cells and b. MM cell viability.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S5. Effect of top pharmacologics on a. inhibition of proteasome ChT-like activity in MM cells and b. MM cell viability.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Figure S19 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S19. Graphical representation to depict the effect of HDAC6 inhibitors on proteasome activity. HDAC6 inhibitors release HR23B which is bound to the HDAC6 BUZ domain. Free HR23B binds and shuttles ubiquitinated cargo proteins to the proteasome. Rad23 binds the proteasome through a UbL (ubiquitin-like) domain and contains UBA (ubiquitin-associated) motifs that bind multi-ubiquitin chains. These domains allow Rad23 to function as a substrate shuttle-factor. Shown is the association of HR23B with the 26S proteasome through interaction with the non-ATPase regulatory subunit 14, also known as Rpn11. The ability of HDAC6 to downregulate HR23B occurs independently of its deacetylase activity.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S19 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S19. Graphical representation to depict the effect of HDAC6 inhibitors on proteasome activity. HDAC6 inhibitors release HR23B which is bound to the HDAC6 BUZ domain. Free HR23B binds and shuttles ubiquitinated cargo proteins to the proteasome. Rad23 binds the proteasome through a UbL (ubiquitin-like) domain and contains UBA (ubiquitin-associated) motifs that bind multi-ubiquitin chains. These domains allow Rad23 to function as a substrate shuttle-factor. Shown is the association of HR23B with the 26S proteasome through interaction with the non-ATPase regulatory subunit 14, also known as Rpn11. The ability of HDAC6 to downregulate HR23B occurs independently of its deacetylase activity.
- Open Access
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S4. a. Effect of hits from the HTS on proteasome ChT-like activity on ARH-77 and U266 MMCLs. Proteasome ChT-like activity was determined with 50,000 ARHG-77 or U266 cells/well after 24 h of incubation with 50 uM LLVY-R110. b. Effect of proteasome inhibitors on proteasome ChT-like activity in three different MMCLs. Bortezomib, carfilzomib and ixazomib were added to MM cells at indicated concentrations. Proteasome ChT-like activity was then determined after 24 h incubation.
- 18 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity
Fig. S4. a. Effect of hits from the HTS on proteasome ChT-like activity on ARH-77 and U266 MMCLs. Proteasome ChT-like activity was determined with 50,000 ARHG-77 or U266 cells/well after 24 h of incubation with 50 uM LLVY-R110. b. Effect of proteasome inhibitors on proteasome ChT-like activity in three different MMCLs. Bortezomib, carfilzomib and ixazomib were added to MM cells at indicated concentrations. Proteasome ChT-like activity was then determined after 24 h incubation.